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Neuropathy of Impaired Glucose Tolerance
and Its Measurement
I
mpaired glucose tolerance (IGT) was
originally shown in the prospective
Whitehall Study (1) to carry an in-
creased risk of large-vessel disease only.
Whether or not IGT may also confer an
increased risk for microvascular compli-
cations is not clear. Although microalbu-
minuria has been shown to be increased
in those with IGT compared with control
subjects (2), the incidence of retinopathy
(IGT 6.7% vs. NGT 5.8%) (3) and mod-
erate neuropathy (IGT 5.7% vs. NGT
2.8%) (4) have been found to be similar.
Nevertheless, it has been proposed
thatIGTmaycauseneuropathy(5).How-
ever, little is new in clinical medicine;
over 40 years ago Ellenberg (see ref. 5)
suggested that neuropathy may indeed
occur in pre-diabetes, although it is inter-
esting that the interpretation was that fac-
tors other than hyperglycemia may cause
the neuropathy. The recent resurgence of
interest in IGT neuropathy is based on
four separate studies of patients with id-
iopathic small-ﬁber neuropathy, where
the prevalence of IGT was found to be
34–35.6%, three times the prevalence in
age-matched control subjects (5). We be-
lieve the interpretation of these studies
has signiﬁcant limitations because the
populations studied were selected for the
presence of idiopathic small-ﬁber neu-
ropathy,ratherthanIGT.Furthermore,as
pointed out by Dyck et al. (6) in a critical
review, the association between IGT and
neuropathyremainstobeconﬁrmedinan
ongoing prospective study. Added to this
the relationship between the metabolic
syndrome, and its component constitu-
ents, to IGT neuropathy has come under
scrutiny. Thus in an earlier study,
whereas 32% of patients with chronic id-
iopathic axonal polyneuropathy com-
pared with 14% of control subjects had
IGT, insulin resistance did not differ be-
tween the two groups; after adjustment
for BMI, age, and sex, only triglycerides
were found to be signiﬁcantly higher in
those with neuropathy (7). This associa-
tion has been conﬁrmed recently in 219
patients with idiopathic peripheral neu-
ropathy compared with 175 diabetic pa-
tients without neuropathy (8). The
prevalence of metabolic syndrome was
comparable in normoglycemic and IGT
patients with neuropathy; however, com-
pared with diabetic subjects without neu-
ropathy, the normoglycemic neuropathy
patients had comparable obesity and hy-
pertension but signiﬁcantly higher total
cholesterol, LDL cholesterol, and triglyc-
erides, with lower HDL cholesterol (8).
This association between the develop-
ment of neuropathy and features of the
metabolic syndrome has previously been
shown in those with type 1 diabetes (9)
andmorerecentlyinanervebiopsystudy
in relation to triglycerides in those with
type 2 diabetes (10).
Two population-based studies have
assessed the prevalence of neuropathy in
IGT: the San Luis Valley (USA) (11) and
the MONICA/KORA Augsburg (Ger-
many) studies (12). Using differing diag-
nostic criteria, the results of these two
epidemiologic surveys are remarkably
similar, with neuropathy present in 11–
13% of IGT and 26–28% of diabetic sub-
jects but also in 4–8% of the nondiabetic
control populations. Although resetting
thediagnosticcriteriaforIGTmaybecon-
sidered unrealistic, a recent analysis has
shown no evidence of a clear and consis-
tent glycemic threshold for the presence
or incidence of retinopathy across three
different populations, suggesting that the
criteria even for diagnosing diabetes may
need reassessment (13).
If we are to undertake a similar anal-
ysisforneuropathy,thechallengeisgoing
to be in relation to the tests used to deﬁne
nerve damage. In the San Luis Valley
study a combination of symptoms, neu-
rological deﬁcits, and vibration percep-
tion threshold was used (11), whereas in
the German study a combination of the
Michigan Neuropathy Screening Instru-
ment, a symptom, and brief neurological
examination was used (12); both studies
are weighted toward large-ﬁber dysfunc-
tion. It has been suggested that future
studiestoaddressIGTneuropathyshould
assess neuropathic clinical signs and
symptoms, electrophysiologic tests, spe-
cialized sensation and autonomic tests,
and perhaps also intraepidermal nerve ﬁ-
bers (IENFs) (6). However, in a recent
study, quantitative sudomotor axon-
reﬂex test responses were signiﬁcantly
impaired in those with IGT compared
with control subjects, indicative of early
distal small-ﬁber neuropathy (14). Simi-
larly, although nerve conduction studies
and cardiac autonomic function tests
were normal, the amplitudes of the sym-
patheticskinresponseswerelowerinIGT
patients (15). Moreover, in 46 subjects
with IGT, an abnormality in four of ﬁve
cardiovascular reﬂex tests, a greater heart
rate variability, and increased heat detec-
tion thresholds have been shown recently
(16).StudiesquantifyingIENFsalsodem-
onstrate that the earliest damage in those
with IGT is to the small ﬁbers (17). In-
deed, these data are supported by studies
in those with early diabetic neuropathy,
where despite normal electrophysiology
and quantitative sensory testing, a signif-
icant reduction in IENF density (IENFD)
hasbeendemonstrated(18,19).Thus,de-
signing a longitudinal study, such as that
of Dyck et al. (6), will require detailed
metabolicandphysicalphenotyping,par-
ticularly in relation to the end points se-
lected to deﬁne neuropathy.
As stated above, the body of evidence
hassuggestedapredominanceofinvolve-
ment of small nerve ﬁbers in the neurop-
athy of IGT, although some preliminary
evidence also supports involvement of
large nerve ﬁbers (20). Nevertheless, skin
biopsies have been proposed to assess
early small-ﬁber damage (21); indeed, a
small study quantifying IENFD has al-
readyshownthatdietarymanagementto-
gether with an exercise program can
result in improvement in IENFD and
painful symptoms in those with IGT neu-
ropathy (22). However, punch skin biop-
sies are still invasive and can cause some
discomfort; a noninvasive alternative
would therefore be preferable, particu-
larly for longitudinal studies. Two such
alternatives exist: First, the technique of
corneal confocal microscopy enables the
direct visualization of small corneal nerve
ﬁbers in vivo, has been shown to detect
small-ﬁber damage earlier than IENFD in
skin biopsies on the dorsum of the foot
(23), and detects nerve repair within 6
months of pancreas transplantation (24).
Second, Krishnan and Rayman (25) pre-
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reﬂex–elicited ﬂare area (LDIﬂare) test and
a test of C-ﬁber function, and Krishnan,
Rayman,andcolleagues(26)showedthat
thesetestsareabnormaldespitepreserved
dermal nerve ﬁber density. In the current
issueofDiabetesCare,Krishnan,Rayman,
and colleagues (27) demonstrate a signif-
icant reduction in the LDIﬂare test with-
out abnormalities in quantitative sensory
testingormaximumhyperemia(LDImax)
in subjects with IGT. These ﬁndings con-
trast with a previous study that demon-
strated a signiﬁcant reduction in LDImax
in a larger group of patients with IGT
(28). It also raises issues regarding the va-
lidity of the LDIﬂare regarding whether it
speciﬁcally measures C- nociceptive ﬁber
function. From a physiological perspec-
tive, thermal (25,26) and pharmacologi-
cal (29,30) stimuli have consistently
induced a nerve axon reﬂex; moreover,
localanesthesiahasbeenshowntoreduce
both the thermal- (25) and acetylcholine-
(29) but not sodium nitroprusside – (30)
mediated response by 70%. Hence, one
can conclude that the nerve axon reﬂex
depends principally but not exclusively
on the function of C-nociceptive ﬁbers
and therefore can be used as a surrogate
measure of small-ﬁber damage.
In conclusion, neuropathic changes
predominantly affecting small ﬁbers ap-
pear to occur more commonly in those
with IGT than in the normal population,
and ongoing prospective studies should
provide conﬁrmation of these initial ob-
servations. If conﬁrmed, an internation-
ally agreed deﬁnition as to what
constitutes IGT neuropathy is required,
andthenoninvasivetechniquesofcorneal
confocal microscopy and LDIﬂare may be
useful in assessing longitudinal cohorts
and potential pharmacological interven-
tionsforwhatisoftenapainfulcondition.
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